Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
GLP-1 receptor agonists may reduce cognitive decline in type 2 diabetes patients with dementia
GLP-1 drugs may slow cognitive decline in type 2 diabetes
A systematic review of systematic reviews and meta-analyses found that GLP-1 receptor agonists are associated with reduced overall cognitive…
A review of reviews suggests GLP-1 drugs like Ozempic may help protect memory and thinking in people with type 2 diabetes.
GLP-1 agonists show short-term metabolic benefit in PCOS but reproductive effects remain uncertain
Doctors suggest GLP-1 drugs help weight but need careful planning before pregnancy in PCOS
A meta-analysis of GLP-1 receptor agonists in PCOS found relatively robust support for short-term metabolic benefit, but reproductive outcom…
New analysis shows GLP-1 drugs help with weight loss for PCOS patients. However, doctors are unsure if these drugs improve fertility and nee…
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
New analysis shows GLP-1 drugs do not raise eye disease risk for diabetes patients
This systematic review and meta-analysis of 28 observational studies found that GLP-1 receptor agonists did not increase the risk of NAION, …
A large review of 28 studies found that diabetes drugs called GLP-1 receptor agonists do not increase the risk of eye problems like glaucoma…
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
New analysis shows GLP-1 drugs cut stroke risk for people with leg artery disease
This systematic review and meta-analysis of over 240,000 adults with peripheral artery disease found that GLP-1 receptor agonists significan…
A large review of real-world data found GLP-1 drugs significantly reduce stroke and heart attack risk in adults with peripheral artery disea…
Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
Real-time glucose monitoring improves blood sugar control in type 2 diabetes
This randomised controlled trial compared real-time continuous glucose monitoring against standard self-monitoring of blood glucose in adult…
A new trial shows continuous glucose monitoring helps lower blood sugar levels better than standard finger-prick testing for adults with typ…
Bariatric surgery yields greater long-term weight loss than GLP-1 receptor agonists in adults with obesity
Bariatric surgery leads to more weight loss than GLP-1 drugs over one year
This meta-analysis compared bariatric surgery against GLP-1 receptor agonists in adults with obesity. While weight loss differences were not…
A large analysis of 20,594 adults found bariatric surgery caused greater weight loss than GLP-1 drugs after one year, with benefits growing …
Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
GLP-1 drugs before weight loss surgery: modest benefit, no extra risk
This meta-analysis of 5461 patients found that preoperative GLP-1 receptor agonist use led to moderate weight reduction (SMD 0.4, 4.87 kg vs…
Taking GLP-1 drugs before bariatric surgery helps drop a few extra pounds but doesn't boost long-term weight loss or raise complication risk…
GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
Review shows GLP-1 drugs may help fatty liver disease
This umbrella review evaluated twenty-three meta-analyses and systematic reviews regarding GLP-1 receptor agonists in patients with metaboli…
A review of many studies suggests GLP-1 receptor agonists may improve fatty liver disease, but the evidence is still early and needs stronge…
Genetic analysis links GLP-1 agonism to pancreatitis risk and sarcopenia in large cohorts
Genetic data link GLP-1 drugs to pancreatitis and muscle loss risks
A Mendelian randomization study of over one million participants suggests GLP-1 receptor agonists causally reduce diabetes risk but may incr…
Genetic analysis suggests GLP-1 receptor agonists may increase pancreatitis risk and muscle loss, while lowering blood sugar and diabetes ri…
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Meta-analysis of Mendelian randomization suggests GLP-1 receptor agonism lowers vascular dementia risk
Genetic data suggests GLP-1 drugs may lower vascular dementia risk
This meta-analysis of Mendelian randomization studies evaluated the association between GLP-1 receptor agonism and dementia risk using genet…
New genetic evidence hints that GLP-1 receptor agonists might lower the risk of vascular dementia, but results for Alzheimer's disease remai…
All GLP-1 receptor agonists Articles
- Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
- GLP-1 receptor agonists may reduce cognitive decline in type 2 diabetes patients with dementia
- GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
- GLP-1 agonists show short-term metabolic benefit in PCOS but reproductive effects remain uncertain
- Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
- Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
- Bariatric surgery yields greater long-term weight loss than GLP-1 receptor agonists in adults with obesity
- GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
- GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
- Genetic analysis links GLP-1 agonism to pancreatitis risk and sarcopenia in large cohorts
- Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
- Meta-analysis of Mendelian randomization suggests GLP-1 receptor agonism lowers vascular dementia risk
- Meta-analysis of GLP-1 agonists for Parkinson's disease motor symptoms shows limited benefit
- Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
- Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
- Narrative review examines multidisciplinary strategies for metabolic syndrome in bipolar disorder
- Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use
- GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
- Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
- Network meta-analysis finds metabolic surgery superior to GLP-1 agonists for weight loss in obesity
- GLP-1 agents and cognitive interventions address obesity and eating disorders via appetite and gut-brain signaling pathways
- Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
- Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
- HFpEF probability scores rule out disease but show limitations in AF and obesity phenotypes
- GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
- FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities
- Lixisenatide shows no effect on arterial stiffness in type 2 diabetes with chronic kidney disease